Novartis, Savient drugs nixed by NICE; Vivus nabs EU approval for Spedra; Aussies aim for sunshine on pharma payments;

@FiercePharma: India suspends Actos on safety concerns. Two other (very old) drugs, too. Report | Follow @FiercePharma

@EricPFierce: FDA goes from passive to aggressive on compounders. I wonder how long before certain Congressmen complain. More | Follow @EricPFierce

@CarlyHFierce: Proxy fight heating up at Vivus... First Manhattan announces search for new CEO candidates. Yesterday's story | Follow @CarlyHFierce

> Novartis' ($NVS) cancer drug Jakavi and Savient's ($SVNT) gout drug Krystexxa got the cold shoulder from U.K. cost-effectiveness watchdogs, who said the drugs were too expensive for use by the National Health Service. Report

> Vivus ($VVUS) won European approval for its erectile dysfunction drug Spedra, more than a year after its clearance from FDA under the brand name Stendra; the company hasn't yet launched in either market. Report

> Medicines Australia, an industry group, unveiled a proposal to require drugmakers to disclose payments to doctors, whether in the form of cash, stock options or food, beginning in 2015. Report

> Ireland's new law encouraging generic use and creating a system of reference pricing went into effect. Report

> India's Dr. Reddy's rolled out its version of the GlaxoSmithKline ($GSK) seizure drug Lamictal in the U.S. Report

> Moody's Japan assigned a (P)Aa3 rating to Takeda Pharmaceutical's shelf registration, which amounts to 250 billion yen, or about $2.54 billion. Release

> Alexion Pharmaceuticals ($ALXN) won an orphan-drug designation for Soliris to treat neuromyelitis optica; the drug is already approved to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Report

Medical Device News

@FierceMedDev: St. Jude takes to Japan with MRI-safe pacer. Story | Follow @FierceMedDev

@DamianFierce: For CROs big and small, you're only as good as your reputation. The view from  DIA 2013. Editor's corner | Follow @DamianFierce

@MichaelGFierce: SEC hammers imaging company, CEO with fraud charges. Report | Follow @MichaelGFierce

> Medtronic warns over pump tied to 14 deaths. Story

> Navidea keys up Alzheimer's Dx agent for Phase III. News

Biotech News

@FierceBiotech: Big Data guru Atul Butte's NuMedii scores $3.5M VC round for 'digital' drug research. FierceBiotech IT story | Follow @FierceBiotech

 @JohnCFierce: Stanley Family Foundation spearheads a $21M round for Heptares - (GPCRs). News | Follow @JohnCFierce

@RyanMFierce: J&J's pharma chairman lands 'more deals' in Boston innovation push. Report | Follow @RyanMFierce

> Celgene jumps into blood-cancer race with J&J, adding $818M MorphoSys deal. Report

> Reverse' DNA vaccine bursts into the spotlight with promising Type 1 diabetes data. News

> Genentech eyes 'breakthrough' cancer immunotherapies in pact with U.K. biotech. Story

> U.S. hands out retirement papers to chimps used for research. Article

Pharma Manufacturing News

> Aspen, Merck deal includes API plants in U.S., Netherlands. Article

> Roche sets out strict expectations for contractors. Report

> Drugmakers more concerned with quality than price in picking CMOs. Item

> FDA spells out its expectations for crude heparin. More

Vaccines News

> Japan faces vaccine shortage in struggle to control rubella. Report

> ACIP rules on GSK, Novartis and Sanofi vaccines. Story

> Corruption alleged as Indian vaccine shortage continues. Item

> Type 1 diabetes vaccine impresses in early study. News

> Takeda tackling norovirus in bid to grow vaccine biz. Article

And Finally... While drugmakers were scouring for counterfeit meds, fake foods have become an epidemic. Report

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.